Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Flamboyant 125/12 in Moderate Asthma
NCT04191434Phase 3Unknown
- Sponsor
- EMS
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol in asthma (2 arms), sponsored by EMS. Primary endpoint: Change from baseline in Forced expiratory volume in 1 second at 12 weeks. Status: unknown.
02
Drugs
budesonide + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04191434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191434.